A retrospective, observational study of perampanel in refractory and super-refractory status epilepticus

The outcomes of administration of Perampanel (PER) is a β-amino-3-(5-methyl-3-oxo-1,2-oxazol-4-yl)propionic acid (AMPA) receptor antagonist for the treatment of refractory status epilepticus (RSE) and Super-refractory (SRSE) were previously reported in small cohort studies and case reports. We report efficacy and side effect results of an observational cohort of 75 patients treated with PER for RSE and SRSE.

from Journal of the Neurological Sciences https://ift.tt/3kUCJ0A